Table 4.
Serotype specific vaccine effectiveness against IPD for ≥ 1 doses of PCV13, by study period.
| Exposure1 | Serotype specific Cases | Non-PCV13-type Controls | Unadjusted | Adjusted2 | ||
|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
| N (%) | N (%) | VE (95 % CI) | VE (95 % CI) | |||
|
| ||||||
| Early PCV13 Implementation (May 1, 2010 - May 31, 2014) | ||||||
| Serotype 19A | No doses of PCV13 | 81 (62.3) | 93 (18.9) | ref. | ref. | |
| ≥1 dose PCV13 | 49 (37.7) | 399 (81.1) | 85.9 (78.7,90.8) | 76.5 (58.9, 86.5) | ||
| Serotype 3 | No doses of PCV13 | 17 (39.5) | 93 (18.9) | ref. | ref. | |
| ≥1 dose PCV13 | 26 (60.5) | 399 (81.1) | 64.4 (32.2,81.5) | 68.2 (19.6, 87.1) | ||
| Serotype 7F | No doses of PCV13 | 30 (93.8) | 93 (18.9) | ref. | ref. | |
| ≥1 dose PCV13 | 2 (6.2) | 399 (81.1) | 98.5 (93.4,99.6) | 98.2 (89.9, 99.7) | ||
| Late PCV13 Implementation (June 1, 2014 - December 31, 2019) | ||||||
| Serotype 19A | No doses of PCV13 | 8 (20.5) | 32 (6.2) | ref. | ref. | |
| ≥1 dose PCV13 | 31 (79.5) | 486 (93.8) | 74.5 (40.4,89.3) | 88.0 (58.2, 96.5) | ||
| Serotype 3 | No doses of PCV13 | 5 (15.6) | 32 (6.2) | ref. | ref. | |
| ≥1 dose PCV13 | 27 (84.4) | 486 (93.8) | 64.5 (2.4,87.3) | 83.5 (11.3, 96.9) | ||
| Serotype 19F | No doses of PCV | 14 (34.1) | 32 (6.2) | ref. | ref. | |
| ≥1 dose PCV13 | 27 (65.9) | 486 (93.8) | 87.3 (73.7,94.0) | 94.1 (80.1, 98.2) | ||
| Full study period (May 1, 2010 - December 31, 2019) | ||||||
| Serotype 19A | No doses of PCV13 | 89 (52.7) | 125 (12.4) | ref. | ref. | |
| ≥1 dose PCV13 | 80 (47.3) | 885 (87.6) | 87.3 (82.0,91.1) | 77.9 (65.6, 85.7) | ||
| Serotype 3 | No doses of PCV13 | 22 (29.3) | 125 (12.4) | ref. | ref. | |
| ≥1 dose PCV13 | 53 (70.7) | 885 (87.6) | 66.0 (42.6,80.1) | 58.4 (19.0, 79.0) | ||
| Serotype 7F | No doses of PCV13 | 30 (93.8) | 125 (12.4) | ref. | ref. | |
| ≥1 dose PCV13 | 2 (6.2) | 885 (87.6) | 99.1 (96.0,99.8) | 97.2 (86.6, 99.4) | ||
| Serotype 19F | No doses of PCV | 15 (33.3) | 53 (5.7) | ref. | ref. | |
| ≥1 dose PCV13 | 30 (66.7) | 885 (94.3) | 88.0 (76.6,94.0) | 92.7 (79.1, 97.3) | ||
Abbreviations: VE = Vaccine Effectiveness; PCV = pneumococcal conjugate vaccine; PCV13- 13-valent pneumococcal conjugate vaccine; CI = confidence interval; ref. = reference level.
For the assessment of Serotype 19A, 3 and 7F VE, participants who received either 7-valent pneumococcal conjugate vaccine (PCV7) or no doses of any pneumococcal vaccination were included in the reference group (No doses of PCV13). For the assessment of Serotype 19F VE, participants were included in the reference group if they received no doses of any PCV products. Persons who received PCV7 only were excluded from this analysis.
Logistic regression model adjusted for age (categorical), race/ethnicity (combined variable), sex, state, calendar year, immunocompromising conditions, chronic conditions or asthma.